Effectiveness of the spot-on combination of moxidectin and imidacloprid (Advocate®) in the treatment of ocular thelaziosis by Thelazia callipaeda in naturally infected cats

Background: The present study evaluated the therapeutic effectiveness of moxidectin 1.0% (w/v) and imidacloprid 10% (w/v) (Advocate® spot-on solution for cats, Bayer Animal Health) against natural infections with the eyeworm Thelazia callipaeda in cats. This study was conducted as a GCP, negative-controlled, blinded and randomised field study in privately owned cats living in an area in southern Italy where T. callipaeda is enzootic. Methods: The study was carried out in 30 cats (19 females and 11 males, aged from 8 months to 5 years, weighing 1.2-5.2 kg) of different breeds, naturally infected by T. callipaeda. At study inclusion (Day 0), animals were physically examined and the infection level was assessed by examination of both eyes for clinical score and live adult T. callipaeda count. Each cat was weighed and randomly assigned to one of the treatment groups (G1: Advocate, G2: untreated control). Clinical assessments and T. callipaeda adult counts were performed on Day 14. At the study completion visit on Day 28, clinical assessments and counts of T. callipaeda adults and larvae were performed. All cats were daily observed by their owners and general health conditions were recorded during the entire period of the study. Results: The primary effectiveness variable was the percentage of animals in G1 group (Advocate) showing a complete elimination (parasitological cure) of adult eye worms at Day 14 and Day 28. The effectiveness of the treatment in the G1 group was 93.3 and 100% at Day 14 and Day 28, respectively, when compared to group G2. Total worm count reduction from both eyes for Advocate was 96.3% on Day 14 and 100% on Day 28. Clinical data were confirmed by the examination of conjunctival pouch flushing. An overall reduction in the number of cats with lacrimation and conjunctivitis was observed following treatment despite the fact that in a few cats treated with Advocate clinical signs persisted due to the chronic nature of the disease. Conclusions: Based on the results of the present trial, a single dose of Advocate was found to be safe and highly effective in the treatment of natural T. callipaeda infection in cats

Evaluation of the Efficacy and Safety of an Imidacloprid 10 % / Moxidectin 1 % Spot-on Formulation (Advocate®, Advantage® Multi) in Cats Naturally Infected with Capillaria aerophila

The parasitic nematode Capillaria (C.) aerophila affects the respiratory system of domestic and wild animals and, albeit rarely, human beings. In cats the infection may be subclinical, or present as chronic bronchitis with various respiratory clinical signs. In Europe there is no licensed product for the treatment of pet capillariosis. The present study aimed to deliver further evidence of the efficacy and safety of a spot-on formulation containing moxidectin 1 % (w/v) and imidacloprid 10 % (w/v) (Advocate (R), Advantage (R) Multi, Bayer) in the treatment of C. aerophila infection in cats when administered once at the approved dose (one pipette 0.4 ml for cats weighing 1-4 kg, one pipette 0.8 ml for cats weighing 4-8 kg). Efficacy was tested on days 7 +/- 1 and 11 +/- 1 following treatment on day 0 and compared to pre-treatment faecal egg counts on days -6 +/- 2 and -2 +/- 2. Overall, 41 cats were enrolled in two groups: G1, treated with Advocate (R) (n=20 cats) and G2, left untreated (n=21 cats). All G1 cats were negative for C. aerophila faecal egg output at the post-treatment evaluation (efficacy: 100 %) while all G2 cats were persistently infested with an average of 195.2 EPG. Differences in mean EPG values were statistically significant (p< 0.001). Of the eleven G1 cats that showed respiratory signs at pre-treatment enrolment, nine fully recovered after the administration of Advocate (R). No adverse events occurred in treated cats. This trial confirmed that Advocate (R) is safe and effective in the treatment of feline lung capillariosis in naturally infected cats

Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy

SARS-CoV-2 emerged from animals and is now easily transmitted between people. Sporadic detection of natural cases in animals alongside successful experimental infections of pets, such as cats, ferrets and dogs, raises questions about the susceptibility of animals under natural conditions of pet ownership. Here, we report a large-scale study to assess SARS-CoV-2 infection in 919 companion animals living in northern Italy, sampled at a time of frequent human infection. No animals tested PCR positive. However, 3.3% of dogs and 5.8% of cats had measurable SARS-CoV-2 neutralizing antibody titers, with dogs from COVID-19 positive households being significantly more likely to test positive than those from COVID-19 negative households. Understanding risk factors associated with this and their potential to infect other species requires urgent investigation

Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy

AbstractSARS-CoV-2 originated in animals and is now easily transmitted between people. Sporadic detection of natural cases in animals alongside successful experimental infections of pets, such as cats, ferrets and dogs, raises questions about the susceptibility of animals under natural conditions of pet ownership. Here we report a large-scale study to assess SARS-CoV-2 infection in 817 companion animals living in northern Italy, sampled at a time of frequent human infection. No animals tested PCR positive. However, 3.4% of dogs and 3.9% of cats had measurable SARS-CoV-2 neutralizing antibody titers, with dogs from COVID-19 positive households being significantly more likely to test positive than those from COVID-19 negative households. Understanding risk factors associated with this and their potential to infect other species requires urgent investigation.One Sentence SummarySARS-CoV-2 antibodies in pets from Italy.</jats:sec

Epidemiology of the eye worm Thelazia callipaeda in cats from southern Switzerland

Thelazia callipaeda is a spiruroid nematode of dogs, cats and wild carnivores transmitted by zoophilic drosophilid Phortica flies and found in an increasing number of European countries. In cats the disease is diagnosed sporadically. This study presents an epidemiological investigation of feline thelaziosis, performed in southern Ticino, Switzerland, an endemic area for T. callipaeda. Between January 2009 and July 2011 2171 cats, having outdoor access and presenting for various reasons, were examined by in-depth eye examinations, and clinical and anamnestic data were collected. The overall prevalence of T. callipaeda in the study area was 0.8% (17/2171 cats, 95% confidence interval: 0.5-1.3%). Among cats showing ocular illness, the prevalence was 9.2% (11/120, CI: 4.7-15.8%). Cats with eye worms had no international travel history and were significantly more often diagnosed between June and December than during other months. With one exception, one single eye per cat was infested, each harboring between 1 and 10 eye worms (arithmetic mean: 2.8 per cat). One cat presented with conjunctivitis and ulcers, seven with conjunctivitis only and 3 with a mildly increased lacrimation, while 6 cats were asymptomatic. Significantly more male than female cats had eye worms and cats older than one year were overrepresented. No pure-bred cats were infested. This study confirms the establishment of this potentially zoonotic parasite in cats from the study area. Due to the clinical relevance and pain caused by the infestations, increased disease awareness and in depth eye examination for the detection of T. callipaeda in cats are recommended, even in absence of obvious clinical signs, in order to initiate appropriate anthelmintic treatment

Evaluation of the efficacy and safety of an imidacloprid 10 %/moxidectin 1 % spot-on formulation (Advocate®, Advantage® Multi) in cats naturally infected by Capillaria aerophila.

Capillaria aerophila is a parasitic nematode affecting the respiratory tract of wildlife, dogs, cats and, occasionally, humans. Infected cats may be asymptomatic, or show various respiratory signs resembling to a chronic bronchitis. No products are licensed in Europe for the treatment of cat capillariosis to date. The aim of the present study was to provide further evidence on the efficacy and safety of a spot-on formulation containing moxidectin 1% (w/v) and imidacloprid 10% (w/v) (Advocate®/Advantage® Multi, Bayer) in the treatment of feline C. aerophila infection when administered once at the approved dose. Efficacy was tested on days 7 ± 1 and 11 ± 1 following treatment on day 0 and compared to pre-treatment faecal egg counts on days -6 ± 2 and -2 ± 2. Forty-one cats were enrolled in two groups: G1, treated with Advocate® (n = 20 cats) and G2, left untreated (n = 21 cats). Cats in G1 cats were negative for C. aerophila faecal egg output at the post-treatment evaluation (efficacy: 100%). Cats in G2 were persistently infected with a mean value of 195.2 EPG. Differences in mean EPG values were statistically significant (p<0.001). Nine out of eleven G1 cats that showed respiratory signs at enrolment fully recovered after the treatment. No adverse events occurred in treated cats. The present study confirmed that Advocate® is efficacious and safe in treating lung capillariosis in naturally infected cats

Monitoring and detection of new endemic foci of canine leishmaniosis in northern continental Italy: An update from a study involving five regions (2018–2019)

Canine leishmaniosis (CanL) is an emerging zoonosis caused by Leishmania infantum and transmitted in southern Europe by phlebotomine sand flies of the subgenus Phlebotomus (Larroussius). Endemic foci of CanL have been recorded in northern continental Italy since early 1990s and attributed to the northward expansion of vector populations due to climatic changes in association with travelling/relocated infected dogs from the southern Mediterranean littoral. In this study, further spread of endemic Leishmania foci was monitored during 2018–2019 in five regions (Aosta Valley, Piedmont, Lombardy, Veneto and Friuli-Venezia Giulia), with focus to territories where investigations were not performed, or they have been inconclusive. Clinical cases of CanL identified by local veterinary practitioners and confirmed by reference diagnosis centers were regarded as autochthonous if their origin from, or travel to, areas endemic for CanL were excluded in the previous ≥2 years. Around these index cases, i) serosurveys for L infantum were carried out where indicated, ii) sampling from potential autochthonous cases in healthy or clinically-suspected resident dogs was intensified by collaborating veterinary practitioners, and iii) suitable sites were investigated for the presence of competent phlebotomine vectors. Fifty-seven municipalities whose enzootic status of CanL was unreported before 2018, were identified as endemic. The stability of 27 foci recorded over the past decade, was also confirmed. Competent phlebotomine vectors, mainly Phlebotomus perniciosus, were collected for the first time in 23 municipalities. The newly recorded endemic municipalities appear to be distributed over a west-to-east decreasing gradient: 30 in Piedmont, 21 in Lombardy, 4 in Veneto and 2 in Friuli-Venezia Giulia. As regards Veneto, it should be noted that a relatively restricted territory was investigated as several municipalities of the region had already been surveyed and detected as endemic for CanL in the past. Cold climate conditions of the easternmost region of Friuli-Venezia Giulia bordering non-endemic territories of Slovenia, are probably less favorable to L infantum transmission

Subcutaneous mast cell tumours: A prospective multi-institutional clinicopathological and prognostic study of 43 dogs

BackgroundCanine subcutaneous mast cell tumours (ScMCTs) reportedly have a good prognosis. However, biomarkers that can be used to predict outcome are currently limited. MethodsA multicentre prospective study was conducted to identify new prognostic markers. Dogs with a first occurrence of ScMCT were enrolled upon primary tumour removal and regional lymphadenectomy. In the absence of metastasis, dogs were monitored, while dogs with overtly metastatic lymph nodes (histological node 3, HN3) received adjuvant vinblastine. ResultsForty-three dogs were enrolled: 15 (34.9%) had at least one HN3 lymph node and received vinblastine, and 28 (65.1%) were monitored. Three tumours harboured exon 8 and 9 c-kit mutations. Eight (18.6%) dogs experienced tumour progression, and five (11.6%) died of MCT-related causes. The 1- and 2-year survival rates were 90% and 77%, respectively. Variables significantly associated with an increased risk of progression included high cytograde, a mitotic count (MC) greater than 4/10 high-power fields (hpf) and Ki67-index greater than 23. An MC greater than 4/10 hpf was also associated with an increased risk of tumour-related death. LimitationsRegional rather than sentinel lymphadenectomy was performed in these dogs. Dogs were enrolled in oncology referral centres, constituting a different population compared to previous studies. ConclusionsScMCTs have a good prognosis. However, the metastatic rate at admission was higher in this study than previously reported, and a subset of tumours were associated with a fatal outcome despite multimodal treatment. Proliferative activity and cytograding may predict more aggressive behaviour in ScMCTs